<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3249">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04366830</url>
  </required_header>
  <id_info>
    <org_study_id>MSB-MSC-ARDS001</org_study_id>
    <nct_id>NCT04366830</nct_id>
  </id_info>
  <brief_title>Intermediate-size Expanded Access Program (EAP), Mesenchymal Stromal Cells (MSC) for Acute Respiratory Distress Syndrome (ARDS) Due to COVID-19 Infection</brief_title>
  <official_title>Intermediate-size Expanded Access of Remestemcel-L, Ex-vivo Cultured Adult Human Mesenchymal Stromal Cells for Acute Respiratory Distress Syndrome Due to COVID-19 Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mesoblast International Sàrl</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mesoblast, Ltd.</source>
  <brief_summary>
    <textblock>
      The objectives of this intermediate-size expanded access protocol are to assess the safety&#xD;
      and efficacy of remestemcel-L in participants with ARDS due to coronavirus infection 2019&#xD;
      (COVID-19).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This intermediate-size expanded access protocol plans to treat approximately 50 adult&#xD;
      participants, male and female, with moderate to severe ARDS due to COVID-19 infection.&#xD;
      Participants who are 18 years of age or older will be enrolled at multiple clinical sites&#xD;
      across the United States.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>No longer available</overall_status>
  <study_type>Expanded Access</study_type>
  <expanded_access_info>
    <expanded_access_type_intermediate>Yes</expanded_access_type_intermediate>
    <expanded_access_type_treatment>Yes</expanded_access_type_treatment>
  </expanded_access_info>
  <condition>Moderate to Severe Acute Respiratory Distress Syndrome Associated With COVID-19</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Remestemcel-L</intervention_name>
    <description>Participants will receive remestemcel-L in two infusions of 2 x 10^6 mesenchymal stromal cells per kilogram (MSC/kg), administered intravenously (IV).</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. 18 years or older&#xD;
&#xD;
          2. Participant has coronavirus disease COVID-19 confirmed by real-time reverse&#xD;
             transcription polymerase chain reaction (RT-PCR) assay or another diagnostic test&#xD;
&#xD;
          3. Moderate to severe ARDS as determined by the following criteria (adapted from the&#xD;
             Berlin criteria):&#xD;
&#xD;
               -  Bilateral opacities must be present on a chest radiograph or computed tomographic&#xD;
                  (CT) scan. These opacities are not fully explained by pleural effusions, lobar&#xD;
                  collapse, lung collapse, or pulmonary nodules.&#xD;
&#xD;
               -  Respiratory failure not fully explained by cardiac failure or fluid overload. An&#xD;
                  objective assessment (e.g., echocardiography) to exclude hydrostatic pulmonary&#xD;
                  edema is required if no risk factors for ARDS are present.&#xD;
&#xD;
               -  Moderate to severe impairment of oxygenation must be present, as defined by the&#xD;
                  ratio of arterial oxygen tension to fraction of inspired oxygen (PaO2/FiO2). The&#xD;
                  severity of the hypoxemia defines the severity of the ARDS:&#xD;
&#xD;
                    -  Moderate ARDS: e PaO2/FiO2 &gt;100 millimeters of mercury (mmHg) and ≤200 mmHg,&#xD;
                       on ventilator settings that include positive end-expiratory pressure (PEEP)&#xD;
                       ≥5 centimeters (cm) of water OR&#xD;
&#xD;
                    -  Severe ARDS: PaO2/FiO2 ≤100 mmHg on ventilator settings that include PEEP ≥5&#xD;
                       cm of water&#xD;
&#xD;
          4. ≤72 hours post-initiation of ventilation&#xD;
&#xD;
          5. High sensitivity C-reactive protein (hs-CRP) serum level ≥ 4.0 milligrams per&#xD;
             deciliter (mg/dL)&#xD;
&#xD;
          6. Acute Physiologic and Chronic Health Evaluation (APACHE II) score ≥5&#xD;
&#xD;
          7. Aspartate aminotransferase/alanine transaminase (AST/ALT) &lt; 5x upper limit of normal&#xD;
             (ULN)&#xD;
&#xD;
          8. Creatinine clearance ≥ 30 milliliters per minute (mL/min)&#xD;
&#xD;
          9. Serum creatinine &lt;2 mg/dL&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Participant is receiving extracorporeal membrane oxygenation (ECMO)&#xD;
&#xD;
          2. Females who are pregnant or lactating&#xD;
&#xD;
          3. Known hypersensitivity to dimethyl sulfoxide (DMSO) or to porcine or bovine proteins&#xD;
&#xD;
          4. Severe chronic obstructive pulmonary disease (COPD) requiring oxygen therapy prior to&#xD;
             becoming ill with ARDS due to COVID-19 infection&#xD;
&#xD;
          5. Any end-stage organ disease which, in the opinion of the treating physician, may&#xD;
             possibly affect the safety of the remestemcel-L treatment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Mahboob Rahman, MD</last_name>
    <role>Study Director</role>
    <affiliation>Mesoblast, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mount Sinai Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 24, 2020</study_first_submitted>
  <study_first_submitted_qc>April 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 29, 2020</study_first_posted>
  <last_update_submitted>April 24, 2020</last_update_submitted>
  <last_update_submitted_qc>April 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ARDS</keyword>
  <keyword>COVID-19</keyword>
  <keyword>Coronavirus</keyword>
  <keyword>MSC</keyword>
  <keyword>remestemcel-L</keyword>
  <keyword>Mesoblast</keyword>
  <keyword>mesenchymal</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Adult</mesh_term>
    <mesh_term>Acute Lung Injury</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

